PDCD1 and hepatocellular carcinoma: Nivolumab and pembrolizumab, both monoclonal antibodies against programmed cell death protein 1 (PD-1) have been approved for treatment of HCC [52,53], although phase III trials failed to reach their primary endpoints to increase overall survival (OS) in patients with non-viral HCC [54].